Aurinia Pharmaceuticals (AUPH) Non-Current Deffered Revenue (2016 - 2026)
Aurinia Pharmaceuticals posted quarterly Non-Current Deffered Revenue of $12.4 million for Q1 2026, little changed year-on-year from $12.4 million in Q1 2025, and down 1.86% on a QoQ basis from $12.6 million in Q4 2025.
Aurinia Pharmaceuticals (AUPH) has 7 years of Non-Current Deffered Revenue data on file, last reported at $12.4 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Deffered Revenue changed 0.3% year-over-year to $12.4 million; the trailing twelve-month figure through Mar 2026 stood at $12.4 million (changed 0.3% YoY), and the FY2025 full-year result was $12.6 million, up 644.44% from the prior year.
- Non-Current Deffered Revenue for Q1 2026 stood at $12.4 million, down from $12.6 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $12.6 million in Q4 2025 and bottomed at $1.7 million in Q4 2024.
- The 3-year median for Non-Current Deffered Revenue is $12.4 million (2025), against an average of $10.6 million.
- The widest annual swing landed in 2025, when Non-Current Deffered Revenue jumped 644.44%; it then dropped 0.3% in 2026.
- A 3-year view of Non-Current Deffered Revenue shows it stood at $1.7 million in 2024, then surged by 644.44% to $12.6 million in 2025, then decreased by 1.86% to $12.4 million in 2026.
- The last three Non-Current Deffered Revenue figures came in at $12.4 million (Q1 2026), $12.6 million (Q4 2025), and $12.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 225.10 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Aurinia Pharmaceuticals | 2.03 Bn | 1.65 Bn | 71.20 Mn | 12.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.41 Mn |
| Dec 31, 2025 | 12.65 Mn |
| Sep 30, 2025 | 12.25 Mn |
| Jun 30, 2025 | 12.35 Mn |
| Mar 31, 2025 | 12.45 Mn |
| Dec 31, 2024 | 1.70 Mn |
| Dec 31, 2019 | 206,000.00 |
| Dec 31, 2018 | 324,000.00 |
| Dec 31, 2017 | 442,000.00 |
| Dec 31, 2016 | 560,000.00 |